SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.
Also called NCT06155604
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT06155604
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Hong Kong SAR China
- Registry status
- Recruiting
Technical summary
Registry record NCT06155604. Randomized; double masking; primary purpose treatment. Start 2023-01-04 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
- Condition
- Lupus Nephritis
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Dapagliflozin 10mg Tab
- Intervention (Drug)
- Standard maintenance therapy
- Lead sponsor
- The University of Hong Kong
Record details
- Record id
cardio:ct-nct06155604- Content hash
00a12c2c1aa23402ace5efdf289f9e6ea84cee3dc8aca1d8fa5cdd0574342f49